Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2009 - 2026)

Vertex Pharmaceuticals' Interest & Investment Income history runs 13 years deep, the most recent figure standing at $114.8 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 2.63% year-over-year to $114.8 million in Q1 2026; TTM through Mar 2026 was $484.8 million, a 9.35% decrease from a year earlier, with the FY2025 full-year figure at $490.9 million, down 17.92% from the prior year.
• Interest & Investment Income eased to $114.8 million in Q1 2026 per VRTX's latest filing, from $121.9 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $181.2 million in Q1 2024 and bottomed at $1.6 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $122.6 million (2023), against an average of $115.3 million.
• Across the five-year window, Interest & Investment Income jumped 7562.5% in 2023 and sank 34.93% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $86.0 million in 2022, then surged by 108.72% to $179.5 million in 2023, then declined by 28.58% to $128.2 million in 2024, then fell by 4.91% to $121.9 million in 2025, then decreased by 5.82% to $114.8 million in 2026.
• Per Business Quant, the three latest VRTX Interest & Investment Income figures stand at $114.8 million (Q1 2026), $121.9 million (Q4 2025), and $125.7 million (Q3 2025).